Research progress on long non-coding RNAs and their roles as potential biomarkers for diagnosis and prognosis in pancreatic cancer

Wang, Yizhi; Zhou, Li; Lü, Jun; Jiang, Bolun; Liu, Chengxi; Guo, Junchao; Xiao, Gary Guishan

doi:10.1186/s12935-020-01550-y

Cited by 14 publications

(11 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several recently conducted researches have pointed out that lncRNA expression disorders actively participate in the development of tumors ( 23 – 27 ). In OSCC, more and more lncRNAs have been shown to be involved in changing the biological functions of tumor cells ( 28 – 30 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long Non-Coding RNA LINC01929 Accelerates Progression of Oral Squamous Cell Carcinoma by Targeting the miR-137-3p/FOXC1 Axis

Che

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Recently, additional long noncoding RNAs (lncRNAs) have been identified and their possible roles were investigated in a variety of human tumors. One of these lncRNAs, LINC01929, promoted the progression of some cancers, whereas its expression and biological function in human oral squamous cell carcinoma (OSCC) remains still mostly uncertain. The LINC01929 expression in OSCC tissues or cell lines was identified via quantitative real-time polymerase chain reaction. The cell counting kit-8, transwell migration, wound-healing, and flow cytometry assays were utilized to characterize the functions of LINC01929 in OSCC cells. The interactive relationships between LINC01929 and miR-137-3p, miR-137-3p and Forkhead box C1 (FOXC1) were investigated by the dual-luciferase activity assay. Our findings demonstrated that LINC01929 was highly expressed in OSCC tissue samples and cell lines, whereas miR-137-3p expression was downregulated. LINC01929 acted as a carcinogenic lncRNA with accelerated OSCC cell proliferation, migration and invasion, and suppression of apoptosis. We further indicated that LINC01929 facilitated tumor growth in xenograft mouse models. Mechanistically, LINC01929 acted as a sponge for miR-137-3p to elevate FOXC1 expression, which is the target of miR-137-3p. In addition, downregulated miR-137-3p expression rescued the suppressive behaviors of LINC01929 knockdown on the biological behaviors of OSCC cells. Taken together, LINC01929 functioned as a tumor-promoting lncRNA via the miR-137-3p/FOXC1 axis in OSCC, suggesting novel targets for OSCC therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Several recently conducted researches have pointed out that lncRNA expression disorders actively participate in the development of tumors (23)(24)(25)(26)(27). In OSCC, more and more -196 (32).…”

Section: Discussionmentioning

confidence: 99%

Long Non-Coding RNA LINC01929 Accelerates Progression of Oral Squamous Cell Carcinoma by Targeting the miR-137-3p/FOXC1 Axis

Che

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Additionally, lncRNA also possess the capacity to act as a miRNA sponge, to perform chromatin remodelling, and promote gene transcription in candidate tumour suppressor genes by binding to gene promotors[ 267 - 270 ]. In terms of the role of lncRNAs as a diagnostic marker in PC a number of candidates have been evaluated with mixed results, and studies are limited to single cohort studies yet to be validated[ 271 ]. Perhaps the most promising study to date in search for a lncRNA biomarker was published in 2020, which utilized analysis of the extracellular vesicle lncRNA profile by extracellular vesicle lncRNA sequencing in patients diagnosed with PC and CP.…”

Section: Serological Biomarkers Of Pcmentioning

confidence: 99%

Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?

O’Neill

Stoita

2021

WJG

View full text Add to dashboard Cite

Pancreatic cancer (PC) is a leading cause of cancer related mortality on a global scale. The disease itself is associated with a dismal prognosis, partly due to its silent nature resulting in patients presenting with advanced disease at the time of diagnosis. To combat this, there has been an explosion in the last decade of potential candidate biomarkers in the research setting in the hope that a diagnostic biomarker may provide a glimmer of hope in what is otherwise quite a substantial clinical dilemma. Currently, serum carbohydrate antigen 19-9 is utilized in the diagnostic work-up of patients diagnosed with PC however this biomarker lacks the sensitivity and specificity associated with a gold-standard marker. In the search for a biomarker that is both sensitive and specific for the diagnosis of PC, there has been a paradigm shift towards a focus on liquid biopsy and the use of diagnostic panels which has subsequently proved to have efficacy in the diagnosis of PC. Currently, promising developments in the field of early detection on PC using diagnostic biomarkers include the detection of microRNA (miRNA) in serum and circulating tumour cells. Both these modalities, although in their infancy and yet to be widely accepted into routine clinical practice, possess merit in the early detection of PC. We reviewed over 300 biomarkers with the aim to provide an in-depth summary of the current state-of-play regarding diagnostic biomarkers in PC (serum, urinary, salivary, faecal, pancreatic juice and biliary fluid).

show abstract

“…Because of better detection and high specificity in the liquid biopsy and tissue, there is increasing interest in exploring the potential of lncRNAs in cancer patients ( 79 , 80 ). Profiling of the lncRNAs derived from extracellular vesicles has helped in the identification of a diagnostic signature for the detection of pancreatic ductal adenocarcinoma ( 81 ).…”

Section: Malat1mentioning

confidence: 99%

Regulation of Hippo, TGFβ/SMAD, Wnt/β-Catenin, JAK/STAT, and NOTCH by Long Non-Coding RNAs in Pancreatic Cancer

Farooqı

Nayyab²,

Martinelli³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Rapidly evolving and ever-increasing knowledge of the molecular pathophysiology of pancreatic cancer has leveraged our understanding altogether to a next level. Compared to the exciting ground-breaking discoveries related to underlying mechanisms of pancreatic cancer onset and progression, however, there had been relatively few advances in the therapeutic options available for the treatment. Since the discovery of the DNA structure as a helix which replicates semi-conservatively to pass the genetic material to the progeny, there has been conceptual refinement and continuous addition of missing pieces to complete the landscape of central dogma. Starting from transcription to translation, modern era has witnessed non-coding RNA discovery and central role of these versatile regulators in onset and progression of pancreatic cancer. Long non-coding RNAs (lncRNAs) have been shown to act as competitive endogenous RNAs through sequestration and competitive binding to myriad of microRNAs in different cancers. In this article, we set spotlight on emerging evidence of regulation of different signaling pathways (Hippo, TGFβ/SMAD, Wnt/β-Catenin, JAK/STAT and NOTCH) by lncRNAs. Conceptual refinements have enabled us to understand how lncRNAs play central role in post-translational modifications of various proteins and how lncRNAs work with epigenetic-associated machinery to transcriptionally regulate gene network in pancreatic cancer.

show abstract

Research progress on long non-coding RNAs and their roles as potential biomarkers for diagnosis and prognosis in pancreatic cancer

Cited by 14 publications

References 98 publications

Long Non-Coding RNA LINC01929 Accelerates Progression of Oral Squamous Cell Carcinoma by Targeting the miR-137-3p/FOXC1 Axis

Long Non-Coding RNA LINC01929 Accelerates Progression of Oral Squamous Cell Carcinoma by Targeting the miR-137-3p/FOXC1 Axis

Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?

Regulation of Hippo, TGFβ/SMAD, Wnt/β-Catenin, JAK/STAT, and NOTCH by Long Non-Coding RNAs in Pancreatic Cancer

Contact Info

Product

Resources

About